Investigators compared the safety and efficacy of polatuzumab vedotin with or without rituximab, gemcitabine, and oxaliplatin in first line for patients with relapsed/refractory diffuse large B-cell ...

Add Yahoo as a preferred source to see more of our stories on Google. Epcoritamab is developed using Genmab's DuoBody technology. Credit: ArDanMe/Shutterstock. Primary results from the global, ...

Investigators saw strong correlation between TTF and PFS for patients with poor prognosis and good prognosis. Time to treatment failure (TTF) is associated with progression-free survival (PFS) across ...

A small extracellular vesicle protein-based model for ovarian cancer relapse detection and monitoring.

Investigators in China evaluated ivonescimab plus chemotherapy for OS and PFS compared with chemotherapy for patients with advanced NSCLC. MPR, a trusted source of medical news and feature content for ...

Divarasib demonstrated superior progression-free and overall survival compared with sotorasib or adagrasib in previously ...